Savant Capital
CTKB icon

Savant Capital’s Cytek Biosciences CTKB Stock Holding History

Savant Capital’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$184K Buy
+30,885
New +$146K ﹤0.01% 2233

Other funds holding CTKB

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
CenterBook Partners
CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Bailard
Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

Savant Capital's CTKB Position: Q3 2026 in Review

Savant Capital opened a new position in Cytek Biosciences (CTKB) in Q3 2026: 30,885 shares worth $184K. The stake represents ﹤0.01% of the portfolio and ranks #2233 among its holdings.

42 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.

  • Savant Capital held 30,885 shares of Cytek Biosciences worth $184K as of Q3 2026.
  • Cytek Biosciences was a new Savant Capital position in Q3 2026.
  • Cytek Biosciences made up ﹤0.01% of Savant Capital's portfolio in Q3 2026, its #2233 holding.
  • 42 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.

Based on Savant Capital's 13F filing for Q3 2026, filed 6 Nov 2026.